{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:53Z","timestamp":1787999873020,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00415-021-10404-0","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T14:07:47Z","timestamp":1611238067000},"page":"2169-2174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Guillain\u2013Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"268","author":[{"given":"Qianqian","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-523X","authenticated-orcid":false,"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"issue":"9","key":"10404_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.2015.65.8427","volume":"34","author":"DS Dizon","year":"2016","unstructured":"Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G (2016) Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 34(9):987\u20131011. https:\/\/doi.org\/10.1200\/JCO.2015.65.8427","journal-title":"J Clin Oncol"},{"issue":"6","key":"10404_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2174\/156800961506150805145120","volume":"15","author":"SC Azoury","year":"2015","unstructured":"Azoury SC, Straughan DM, Shukla V (2015) Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets 15(6):452\u2013462. https:\/\/doi.org\/10.2174\/156800961506150805145120","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10404_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12885-019-5266-4","volume":"19","author":"H Bahig","year":"2019","unstructured":"Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Soulieres D, Guertin L, Filion E, Christopoulos A, Lambert L, Tehfe M, Ayad T, Charpentier D, Jamal R, Wong P (2019) Phase I\/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer 19(1):68. https:\/\/doi.org\/10.1186\/s12885-019-5266-4","journal-title":"BMC Cancer"},{"key":"10404_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2018.12.015","volume":"130","author":"MA Gubens","year":"2019","unstructured":"Gubens MA, Sequist LV, Stevenson JP, Powell SF, Villaruz LC, Gadgeel SM, Langer CJ, Patnaik A, Borghaei H, Jalal SI, Fiore J, Saraf S, Raftopoulos H, Gandhi L (2019) Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer 130:59\u201366. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.015","journal-title":"Lung Cancer"},{"issue":"7","key":"10404_CR5","first-page":"3212","volume":"12","author":"Q Zheng","year":"2020","unstructured":"Zheng Q, Xu J, Gu X, Wu F, Deng J, Cai X, Wang G, Li G, Chen Z (2020) Immune checkpoint targeting TIGIT in hepatocellular carcinoma. Am J Transl Res 12(7):3212\u20133224","journal-title":"Am J Transl Res"},{"issue":"2","key":"10404_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin 70(2):86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10404_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","volume":"18","author":"C Astaras","year":"2018","unstructured":"Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF (2018) Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 18(1):3. https:\/\/doi.org\/10.1007\/s11910-018-0810-1","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"10404_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/annonc\/mdr028","volume":"22","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Neyns B (2011) Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 22(4):991\u2013993. https:\/\/doi.org\/10.1093\/annonc\/mdr028","journal-title":"Ann Oncol"},{"issue":"8","key":"10404_CR9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","volume":"142","author":"A Jacob","year":"2016","unstructured":"Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S (2016) A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol 142(8):1869\u20131870. https:\/\/doi.org\/10.1007\/s00432-016-2191-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"10404_CR10","unstructured":"Bristol-Myers Squibb Company, Princeton, NJ (2020) YERVOY\u00ae (ipilimumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s115lbl.pdf. Accessed 25 November 2020"},{"key":"10404_CR11","unstructured":"Bristol-Myers Squibb Company, Princeton, NJ (2020) OPDIVO\u00ae (nivolumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125554s089lbl.pdf. Accessed 25 November 2020"},{"key":"10404_CR12","unstructured":"Merck Sharp and Dohme Corp, Whitehouse Station, NJ (2020) KEYTRUDA\u00ae (pembrolizumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s084lbl.pdf. Accessed 25 November 2020"},{"key":"10404_CR13","unstructured":"Genentech Inc, South San Francisco, CA (2020) TECENTRIQ\u00ae (atezolizumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s029lbl.pdf. Accessed 25 November 2020"},{"key":"10404_CR14","unstructured":"EMD Serono Inc, Rockland, MA (2020) BAVENCIO\u00ae (avelumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761049s009lbl.pdf. Accessed 25 November 2020"},{"key":"10404_CR15","unstructured":"AstraZeneca Pharmaceuticals LP, Wilmington, DE (2020) IMFINZI\u00ae (durvalumab) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761069s020lbl.pdf. Accessed 25 November 2020"},{"key":"10404_CR16","unstructured":"Regeneron Pharmaceuticals Inc, Tarrytown, NY (2020) LIBTAYO\u00ae (cemiplimab-rwlc) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761097s005lbl.pdf. Accessed 25 November 2020"},{"issue":"1","key":"10404_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ (2013) A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36(1):77\u201378. https:\/\/doi.org\/10.1097\/CJI.0b013e31827807dd","journal-title":"J Immunother"},{"issue":"3","key":"10404_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF de Maleissye","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375(3):296\u2013297. https:\/\/doi.org\/10.1056\/NEJMc1515584","journal-title":"N Engl J Med"},{"issue":"1","key":"10404_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10404_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database. J Neurooncol 145(1):1\u20139. https:\/\/doi.org\/10.1007\/s11060-019-03273-1","journal-title":"J Neurooncol"},{"issue":"12","key":"10404_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","volume":"27","author":"C Fukazawa","year":"2018","unstructured":"Fukazawa C, Hinomura Y, Kaneko M, Narukawa M (2018) Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf 27(12):1402\u20131408. https:\/\/doi.org\/10.1002\/pds.4672","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10404_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93(6):539\u2013546. https:\/\/doi.org\/10.1038\/clpt.2013.24","journal-title":"Clin Pharmacol Ther"},{"key":"10404_CR23","unstructured":"MedDRA MSSO (2020) Introductory guide for standardised MedDRA queries (SMQs) Version 23.0. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_23_0_English.pdf. Accessed 25 November 2020"},{"key":"10404_CR24","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti FD (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Data mining applications in engineering and medicine. https:\/\/api.intechopen.com\/chapter\/pdf-preview\/38579. Accessed 25 November 2020","DOI":"10.5772\/50095"},{"issue":"1","key":"10404_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10404_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10404_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10404_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf 25(6):381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001","journal-title":"Drug Saf"},{"issue":"7","key":"10404_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"issue":"1","key":"10404_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12911-019-0999-1","volume":"19","author":"R Liu","year":"2019","unstructured":"Liu R, Zhang P (2019) Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. BMC Med Inform Decis Mak 19(1):279. https:\/\/doi.org\/10.1186\/s12911-019-0999-1","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"10404_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D, Psimaras D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30(6):659\u2013668. https:\/\/doi.org\/10.1097\/WCO.0000000000000503","journal-title":"Curr Opin Neurol"},{"key":"10404_CR32","unstructured":"World Health Organization (2016) Guillain\u2013Barr\u00e9 syndrome. http:\/\/www.who.int\/mediacentre\/factsheets\/guillain-barre-syndrome\/en. Accessed 25 November 2020"},{"issue":"24","key":"10404_CR33","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki N, Hartung HP (2012) Guillain-Barre syndrome. N Engl J Med 366(24):2294\u20132304. https:\/\/doi.org\/10.1056\/NEJMra1114525","journal-title":"N Engl J Med"},{"issue":"11","key":"10404_CR34","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1634\/theoncologist.2017-0673","volume":"23","author":"JM O'Connor","year":"2018","unstructured":"O\u2019Connor JM, Seidl-Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP (2018) Disparities in the use of programmed death 1 immune checkpoint inhibitors. Oncologist 23(11):1388\u20131390. https:\/\/doi.org\/10.1634\/theoncologist.2017-0673","journal-title":"Oncologist"},{"key":"10404_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8070232","author":"A Irelli","year":"2020","unstructured":"Irelli A, Sirufo MM, D\u2019Ugo C, Ginaldi L, De Martinis M (2020) Sex and gender influences on cancer immunotherapy response. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8070232","journal-title":"Biomedicines"},{"issue":"6809","key":"10404_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/35041694","volume":"408","author":"RA DePinho","year":"2000","unstructured":"DePinho RA (2000) The age of cancer. Nature 408(6809):248\u2013254. https:\/\/doi.org\/10.1038\/35041694","journal-title":"Nature"},{"issue":"2","key":"10404_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 36(2):123\u2013133. https:\/\/doi.org\/10.1159\/000324710","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10404_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0000000000000193","volume":"19","author":"S Supakornnumporn","year":"2017","unstructured":"Supakornnumporn S, Katirji B (2017) Guillain-Barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis 19(2):80\u201383. https:\/\/doi.org\/10.1097\/CND.0000000000000193","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10404-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10404-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10404-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T14:13:39Z","timestamp":1622902419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10404-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10404"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10404-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was waived by the Institutional Review Board of Peking Union Medical College Hospital because this was an observational study based on the FAERS, which is a public anonymized database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}